Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia

Tomohiko Akahoshi, Morimasa Tomikawa, Hirofumi Kawanaka, Norihiro Furusyo, Nao Kinjo, Norifumi Tsutsumi, Yoshihiro Nagao, Jun Hayashi, Makoto Hashizume, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Background and Aim: We intended to determine whether laparoscopic splenectomy (Lap-Sp) contributes to treatment with interferon therapy in hepatitis C virus (HCV)-cirrhotic patients with thrombocytopenia caused by hypersplenism. Methods: From December 2004 to August 2008, 100 cirrhotic patients (54 men and 46 women) underwent Lap-Sp for a clinical application of interferon therapy. All the patients were Child-Pugh class A or B with thrombocytopenia (average platelet count, 56×103/mm3). The HCV genotype was type 1 in 80 patients and type 2 in 20 patients. Results: Pure laparoscopic or hand-assisted laparoscopy was performed in 78 and 22 patients, respectively, without mortality. Conversion to open surgery was not required in any of the patients. The platelet counts improved (mean platelet count 172×103/mm3 1month after surgery) and interferon (IFN) therapy was started in 97 patients. In this study period, 36 patients obtained a sustained virologic response. Eight patients discontinued IFN therapy because of depression, neutropenia or other reasons. Conclusions: Lap-Sp permits most patients with HCV cirrhosis and hypersplenism to receive sufficient IFN therapy. Therefore, Lap-Sp can become a strong supportive surgery for cirrhotic patients who require antiviral therapy.

Original languageEnglish
Pages (from-to)286-290
Number of pages5
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume27
Issue number2
DOIs
Publication statusPublished - Feb 2012

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia'. Together they form a unique fingerprint.

Cite this